Abstract Lactose is widely used as a carrier of drugs in inhalation devices for asthmatic patients, but some clinicans have suspected that it may cause bronchoconstriction.Only a few studies have been done to examine this and the results are not uniform.This study was conducted to determine the e¡ects of inhalation grade lactose delivered by Diskhaler TM on lung function and airway conductance in asthmatic subjects.The e¡ect of ¢ve doses of lactose ranging from 6?25 mg to 100 mg and placebo were investigated using spirometry and constant volume plethysmography. Nineteen subjects (nine females) with stable asthma and a proven reversibility of at least 12% in forced expiratory volume in 1 sec (FEV 1 ) (compared to baseline) in the last 6 months, were included in this single-centre, randomized, placebo-controlled, double-blind, cross-over study.The subjects received placebo plus ¢ve doses of lactose on one study day and six doses of placebo on another study day. Both doses and study days were assigned in a random order, and intervals of 1h were allowed between each dose and at least 36 h between study days. Speci¢c airways conductance (sG aw ) and FEV 1 were measured periodically over the course of 1h after each dose of lactose or placebo. Administration of lactose at four or eight times the concentration in the Diskus TM and Diskhaler TM dry powder inhalers did not result in any statistically signi¢cantchangesin FEV 1 . sG aw also showed no statistical di¡erence betweenlactose and placebo at1or 3 min post-dosing. Both placebo and lactose produced both dilatation and constriction of the airways in the same patients, with no consistency in direction and no dose^response relationship. No adverse e¡ect of lactose on airways conductance or FEV 1 of stable asthmatic patients was found in this study when given at higher than normal clinical doses.
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INTRODUCTION
Dry powder inhalers (DPI) have been introduced to help overcome the co-ordination problems experienced by some patients using pressurized metered dose inhalers (MDIs). Most DPIs are breath-actuated devices which rely on the patient's inhalation to dispense a dose of drug, the e⁄ciency of their delivery depending on the inhalation manoeuvre, the design of the inhaler and the formulation of the inhalation powder (1) . Because the micronized drug particles in dry powders are very cohesive and have poor £ow properties they are generally mixed with larger inert carrier particles, most commonly lactose, to make the powder blend less cohesive and more free-£owing (2) . This helps to ensure accurate dosing as small amounts of drug can be measured into individual factory dispensed doses, and also improves the emptying of the micronized materials from the delivery system (3, 4) . During inhalation the drug particles are separated from the surface of the carrier particles by the energy of the inspired air£ow.
Lactose ful¢ls many of the requirements of an ideal carrier, being readily available in a pharmaceutical grade, chemically and physically stable, and inert to most drug substances (5) .Other carriers used include trehalose and manitol, which are sugar structures similar to lactose (6). Another important requirement for an ideal carrier is that it should be readily cleared from the airways and have no harmful e¡ects on the respiratory tract: little is known about the e¡ect of inhaled lactose on airways function, however. It has been suggested fromin vitro data that lactose may cause in£ammation and mucus discharge in the human nasal mucosa (7), and some patients have reported irritation and chest tightness after inhalation of dry powder (8) .Data from two studies speci¢cally to investigate the e¡ects of inhaling lactose have shown con£icting results, however. One showed that inhalation of a total dose of 600 mg of lactose over 20 min showed little bronchoconstrictor or irritant e¡ect on the airways of asthmatic subjects (9) , while the other (uncontrolled) study found that 25 mg lactose caused a signi¢cant decrease in airways conductance 1^3 min post-dosing (8) . This study was therefore designed to investigate the e¡ect of di¡erent concentrations of lactose on pulmonary function in stable asthmatic subjects, in a double blind, placebo-controlled manner. Airway function was assessed by forced expiratory volume in 1 sec (FEV 1 ) obtained by spirometry, and speci¢c airways resistance and conductance measurements, obtained by constant volume plethysmography.
METHODS Patients
Nineteen subjects aged 18^57 years with a history of asthma were randomized from 20 subjects screened. At screening all patients had to either have a documented history of reversibility !12% in FEV 1 [or !20% peak expiratory £ow (PEF)] within the previous 6 months, or demonstrate similar reversibility to 800 mg of salbutamol after withholding bronchodilator for !6 h. Patients who were receiving short-acting b 2 -agonists as required and were able to use the Diskhaler TM correctly were included. All study subjects were symptom-free at the pre-study visit: one had wheezing on forced expiration. Patients who had experienced an exacerbation of asthma and required a change in their usual asthma medication, required either oral steroids or antibiotics, or had been hospitalized for their respiratory disease within 4 weeks of the screening visit, were excluded. Also excluded were patients who had used long-acting b 2 -agonists within 2 weeks of the screening visit, who smoked 420 cigarettes a day regularly or had a smoking history of 20 pack-years, were pregnant or lactating, had known intolerance to lactose, or had clinical or laboratory evidence of serious uncontrolled systemic disease.
Study design
This was a single-centre, randomized, double-blind, placebo-controlled, cross-over study. There were three study visits: a pre-study visit to assess eligibility and two study days on which treatments were administered. On one study day patients received lactose or placebo (empty blisters) on six occasions, while on the other they received six doses of placebo.The order of the study days was randomized and, to avoid any carry-over e¡ect, they were separated by at least 36 h. The doses of lactose administered were 6?25 mg, 12?5 mg, 25 mg, 50 mg and 100 mg, representing doses up to eight times that used clinically in a Diskus TM *, or four times that in a Diskhaler TM *.We think these doses represent the highest likely to be taken at one time by patients in a clinical situation, and they are equivalent to the maximum dose deliverable from one four-place Rotadisk TM *. Each study dose was separated by 1h from the previous one and the order of doses was randomized.
On a study day, each patient was given a treatment pack consisting of six four-place Diskhalers TM pre-loaded with Rotadisks TM containing di¡erent doses of lactose or placebo.There was no more than 25 mg inhalation grade lactose powder in each blister (the dose present in commercial Rotadisk TM blisters). The six di¡erent Rotadisks TM were as follows:
Four placebo (empty) blisters; One lactose 6?25 mg blister and three placebo blisters; One lactose12?5 mg blister and three placebo blisters; One lactose 25 mg blister and three placebo blisters; Two lactose 25mg blisters and two placebo blisters; Four lactose 25 mg blisters.
Doses were administered by taking all four blisters of a Rotadisk TM in quick succession, the timing of the lung function assessments being measured from the point that the last blister was inhaled. On the placebo day all Diskhalers TM were loaded with placebo Rotadisks TM (empty blisters); this was included to control for any e¡ect due to non-lactose factors such as bronchoconstriction due to rapid inspiration of ambient air. Patients were asked to avoid ca¡eine during study days and for at least 6 h beforehand.The use of short acting b 2 -agonists within 6 h before a visit was also not permitted.
Ethics
Ethics Committee and Regulatory Authority approvals were both obtained prior to commencement of the study, and all patients gave their written informed consent to participate in the study before entry.
Measurement of lung function
Airway calibre was assessed by measuring speci¢c airways conductance (sG aw ) in a constant volume whole body plethysmograph ('body box') (Master Lab Body, Erich Jaeger GMBHA, Hoechberg, Germany). Patients remained in the plethysmograph for each set of sG aw readings but were then allowed to leave it and relax until shortly before the next dosing occasion. Following baseline assessment (t = 0), patients inhaled lactose powder or placebo and measurements were taken at1, 3, 5,10 and 15 min afterwards. FEV 1 was measured outside of the body box at 10 min before the ¢rst dose, and at 20 and 50 min after each dose for all doses (the 50 min measurement acting as the 710 measurement for the next dose). Three FEV 1 measurements were taken at each time point and the highest recorded.
Safety assessments
These comprised the recording of clinical adverse events throughout the study, and of baseline pulmonary auscultation and vital signs (pulse rate and blood pressure) at visit 1 to assess suitability for the study. Patients were asked how they felt and have their lung function monitored throughout the two study days. Patients with a known hypersensitivity to lactose were excluded from the study.
Statistical methods

Sample size
There was insu⁄cient published data to allow a proper sample size calculation to be made. Our previous study (8) had demonstrated signi¢cant ¢ndings with 15 patients, so the sample size in this study was based on practical rather than statistical considerations, with the aim of recruiting 20 patients to get 18 randomized.
E⁄cacy analysis
The FEV 1 recorded 10 min prior to dosing was taken as the baseline value for each dose, and the one at 20 min after dosing represented the post-dosing value. Results were summarized using summary statistics (n, mean, standard deviation, minimum and maximum) and the percentage change from baseline was calculated. The percentage change from baseline was analysed using analysis of covariance with the subject identi¢er, study day (1st or 2nd), dosing order from 1st to 6th dose and the baseline value included as covariates.
For sG aw the baseline was taken as the measurement immediately prior to dosing (t=0), and the measurements to be analysed were made at1and 3 min after dosing.The analysis was the same as for FEV 1 . Measurements after 3 min were not analysed statistically so as to minimize the number of comparisons and preserve the power of the study: our previous study (8) suggested that any changes in sG aw would be seen in the ¢rst 3 min.The data were, however, available to allow the duration of any effects to be determined.
All concentrations of lactose were compared to placebo. For the statistical comparison, the seven sets of placebo measurements for each subject (six from the placebo day and one from the lactose day) were all included in each analysis.
RESULTS
Twenty patients were recruited into the study, of whom 19 ful¢lled the inclusion criteria and were randomized, and received at least one dose of study medication. One patient was withdrawn after randomization due to an exacerbation of asthma after attending one study day (placebo only), otherwise all randomized patients completed all study procedures and assessments. Eight of the patients were current or ex-smokers, with a mean history of 5?1 pack-years (maximum 15 packyears). The demographic details of the patients are shown inTable 1.
E⁄cacy
FEV 1
Inhaling placebo resulted in an increase in FEV 1 of 2?22% at 20 min post-dosing compared to the pre-dosing value. By comparison, lactose at the lowest concentration (6?25 mg) resulted in a 1?95% increase in FEV 1 ( Fig. 1; Table 2 ). Higher concentrations of lactose: 12?5 mg, 25 mg, 50 mg and 100 mg, resulted in changes in FEV 1 of 0?24%, 2?96%, 0?5% and 70?7%, respectively. There was no evidence of a trend in changes in FEV 1 with increasing lactose dose and there were no statistically signi¢cant di¡erences between any dose of lactose and placebo ( Table 2 ).The adjusted mean di¡erence between lactose and placebo varied between 72?2% (100 mg dose) and +1?8% (25 mg dose), and there were no statistically signi¢cant di¡erences between any dose of lactose and placebo. *ANCOVA on the % change from pre-dosing with covariates of patient, study day, time and baseline sG aw included.
(6?25 mg dose) and +6?32% (25 mg dose) compared to pre-dosing. There was no evidence of any trend with increasing lactose dose and there were no statistically signi¢cant di¡erences between any dose of lactose and placebo. The adjusted mean di¡erence between lactose and placebo varied between 75?0% (50 mg dose) and +4?3% (25 mg dose) at 1min postdosing, and there were no statistically signi¢cant di¡er-ences between any dose of lactose and placebo nor dose-related trend. The data at 3 min showed a similar lack of statistical signi¢cance and trend, and smaller differences than at 1min.
Safety
Only one adverse event was reported during the study: an exacerbation of asthma which occurred 5 days after the patient had attended their ¢rst study day and received placebo only. The event was assessed as not related to the study drug and the patient was subsequently withdrawn from the study. No serious adverse events were reported.
DISCUSSION
There is little published data on the e¡ect of lactose on airways function as opposed to its e¡ects on patient preference or dosing perception. One study in 10 asthmatics with known bronchial hyper-responsiveness to methacholine (9) found little or no e¡ect on FEV 1 of 600 mg lactose administered over 20 min with the authors concluding that the majority of the bronchoconstriction was due to the forced expiratory volume manoeuvre itself. In our previous study in15 asthmatics with FEV 1 reversibility 415% (8), however, we found a signi¢cant reduction in speci¢c airways conductance (sG aw ) 1^3 min after 25 mg lactose and concluded that lactose could cause bronchoconstriction in asthmatics. Our previous study, though, was uncontrolled, and so we set out to examine both FEV 1 and sG aw over a range of doses of lactose in a double-blind, placebo-controlled study. For FEV 1 we found only small variations after inhaling empty blisters (placebo) or lactose, and no statistically signi¢cant di¡erences between lactose and placebo. The changes we saw probably represent the natural variability of the measurement, therefore, and we concurred with the results of Shaw et al. (9) by failing to ¢nd any clinically relevant reduction in FEV 1 .
The plethysmography data supported the conclusions from the FEV 1 results. sG aw at 1 and 3 min after inhaling again showed variable small changes not apparently related to lactose dose, and did not show any statistically signi¢cant di¡erences between lactose and placebo.
Our previous study, where we found a signi¢cant e¡ect of 25 mg lactose on sG aw (8) , was a smaller, open label study using only a single dose of lactose and no empty blisters for control. In addition, the subjects had a reversibility 415% at baseline and were symptomatic, compared with a proven reversibility of 412% in the last 6 months and stable asthma for those in the current study. The decrease of sG aw after lactose at 1 and 3 min in our previous study could simply have been a consequence of the inspiratory manoeuvre itself in those more symptomatic subjects or of being 'locked in' the body box, and hence unrelated to the presence of lactose. In the present study we controlled for these factors by administering placebo blisters, and did not detect any signi¢cant decrease from baseline at 1 or 3 min or di¡erences between lactose and placebo. Further studies of this type would be needed to de¢nitively exclude bronchoconstriction due to lactose powder in patients with unstable asthma. No increase in bronchoconstriction episodes was reported in a recent study of prednisonedependent severe asthmatics whose oral steroid was replaced by a lactose-containing formulation (Diskus TM ) of £uticasone propionate (14) , however, and their FEV 1 improved after the change. It is probable therefore that in clinical situations lactose powder either exerts no e¡ect on severe/unstable asthma, or an imperceptible one in relation to the e¡ect of the drug given.
Concerns about the theoretical risks of lactose should be weighed against the bene¢ts from its inclusion. Carriers such as lactose aid the £ow and dispersion properties of dry powder formulations, helping the delivery of a high ¢ne particle fraction of drug to the lung while the carrier remains in the upper airways. This has been shown for lactose formulations from the Diskus TM inhaler, for example, by consistent emission of drug in the ¢ne particle range and consistency of dosing close to the label claim (10, 11) . Radiolabelling has shown that there is high oropharyngeal deposition of inhaled lactose with only a small percentage deposited in the lungs (12) .
As well as aiding dispersion, lactose also helps patients to perceive that they have taken a dose, thus aiding treatment compliance (13) . Indeed, some patients have complained when given DPIs that deliver drug without a lactose carrier that the devices are not working (13) , whilst a small proportion do not appreciate the taste sensation. There are good reasons, therefore, for including a lactose carrier in an inhaled dry powder formulation so long as it is safe, and it is used in a number of di¡erent inhalers, for example Diskus To our knowledge the highest single dose of lactose delivered by these devices is 25 mg. Our study found that lactose powder, at doses at least four times higher than those used commercially in inhalers, produced no evidence of any clinically relevant changes in airway function in stable asth-{ Turbuhaler TM is a trademark of Astrazeneca. { Easyhaler TM is a trademark of Orion Pharma.
matics, and so is probably safe for use in this patient group. In summary, this study showed that high concentrations of lactose were not associated with any clinically important changes in FEV 1 or airway conductance in stable asthmatic subjects. No statistically signi¢-cant di¡erence from placebo was observed. The small changes seen showed no consistency in direction and no dose^response relationship, and are likely to be attributable to the subject variation and measurement techniques. More work needs to be done to con¢rm its safety in other parameters. Lactose is therefore not only a useful additive in dry powder inhalers, with regards to FEV 1 and airways conductance, it is probably also a safe one.
